Houston, Texas 77030

  • Metastatic Malignant Neoplasm in the Spine


This trial studies how well standard and delayed fludeoxyglucose F-18 (FDG)-positron emission tomography (PET)/computed tomography (CT) given after standard radiation and chemotherapy works in assessing patients with head and neck squamous cell cancer that has spread to other places in the body. Diagnostic procedures, such as PET/CT, use radioactive material, such as fludeoxyglucose F-18, to find and diagnose head and neck tumors and may help to find out how far the disease has spread.

Study summary:

PRIMARY OBJECTIVE: I. To assess the optimal imaging time using FDG positron emission tomography (PET) with comparison between a standard of care 1-hour scan (early) and the research scan of 3-hours scan (delayed) post radiotracer administration that maximizes separation of activity between lesion and non-lesional parenchyma (measured as lesion/background [L/B] ratio) in patients with head and neck primary squamous cell carcinoma following chemoradiation treatment. OUTLINE: Patients receive fludeoxyglucose F-18 intravenously (IV) over 1 minute and undergo PET/CT at 70 and 180 minutes after injection at 12-14 weeks following standard chemoradiation (CRT) completion. After completion of study, patients are followed up at 30 days and then periodically for up to 6 months.


Inclusion Criteria: - Adult with computed tomography (CT) or fludeoxyglucose F-18 (FDG) positron emission tomography (PET) findings of cervical nodal metastasis from a head and neck primary squamous cell carcinoma treated with definitive chemoradiation Exclusion Criteria: - Children - No evidence of cervical nodal metastasis - Active infection of the head and neck - Known allergy to FDG, iodine or gadolinium-based contrast agents - Blood glucose (> 250 mg/dl) - Severe renal dysfunction (glomerular filtrate rate [within 30 days] less than 30) - Pregnant women



Primary Contact:

Principal Investigator
Jason M Johnson
M.D. Anderson Cancer Center

Jason Johnson
Phone: 713-792-8443
Email: jjohnson12@mdanderson.org

Backup Contact:


Location Contact:

Houston, Texas 77030
United States

Jason M. Johnson
Phone: 713-792-8443
Email: jjohnson12@mdanderson.org

Site Status: Recruiting

Data Source: ClinicalTrials.gov

Date Processed: June 23, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.